Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Santen Pharmaceutical Co ( (JP:4536) ) just unveiled an announcement.
Santen Pharmaceutical reported weaker consolidated results for the nine months ended December 31, 2025, with revenue declining 5.4% year on year to ¥210.8 billion and core operating profit dropping 20.3%, reflecting profit pressure despite a still-solid earnings base. Net profit attributable to owners of the company fell 20.6%, although total comprehensive income rose 54.9%, and the balance sheet remained strong with an equity ratio above 70%. The company kept its full-year forecast for the fiscal year ending March 31, 2026 unchanged, projecting slight declines in revenue and profit versus the previous year, and confirmed an increase in annual dividends from ¥36 to ¥38 per share, signaling continued shareholder returns even as operating performance softens. Santen also cancelled a portion of its treasury shares in November 2025, which has been factored into earnings per share forecasts but does not alter its overall earnings outlook.
The most recent analyst rating on (JP:4536) stock is a Hold with a Yen1722.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a Japan-based healthcare company listed on the Tokyo Stock Exchange Prime Market, specializing in ophthalmic pharmaceuticals and related eye-care products. The company focuses on prescription and over-the-counter treatments for eye diseases, aiming to strengthen its position in the global ophthalmology market.
Average Trading Volume: 897,885
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen566B
Find detailed analytics on 4536 stock on TipRanks’ Stock Analysis page.